Sigma-Aldrich Completes Acquisition of Cell Marque

Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and High Technology company, announced it has completed its acquisition of Rocklin, California based Cell Marque Corporation, an industry-leading provider of in vitro diagnostic (IVD) antibody reagents and kits. The Company expects this acquisition to be neutral to mildly accretive to earnings per share in 2015. Terms of the transaction were not disclosed.

"We are pleased that Cell Marque is now part of Sigma-Aldrich. Our customers in clinical pathology and clinical laboratories worldwide will benefit from Cell Marque's extensive validation process of immunohistochemistry (IHC) diagnostic reagents, which, ultimately, leads to better patient management," said Theresa S. Creasey, Ph.D., Vice President, Diagnostics & Testing of Sigma-Aldrich's Applied Business Unit. "We welcome the Cell Marque team to Sigma-Aldrich and look forward to leveraging their vast scientific knowledge and expertise to augment our extensive capabilities in this emerging area."

Cell Marque is a well-recognized provider of diagnostic reagents widely used in IHC. With its high quality products and technical expertise, including validated, fit-for-purpose antibodies and IHC staining kits aimed at pathologists and clinicians focused on patient management, Cell Marque has earned a great deal of industry recognition. Cell Marque's products and scientific expertise will complement Sigma-Aldrich's workflow solutions aimed at IVD customers.